Apolipoprotein B (Apo-B) Test
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
1
Biomarkers
Blood (serum)
Sample
1–3 business days
Turnaround
No — apolipoprotein B is reliable in the non-fasting state, consistent with modern lipid guidance
Fasting
What is the Apo-B test?
The Apolipoprotein B Test measures the structural protein carried by every atherogenic lipoprotein particle, providing a direct count of the total number of atherogenic particles in the circulation. Because each LDL, VLDL, IDL, and lipoprotein(a) particle carries exactly one apolipoprotein B, the concentration captures particle burden in a way that the cholesterol content measured by a standard lipid panel does not. In the diagnostic landscape, apolipoprotein B is increasingly recognised as a more reliable marker of atherogenic risk than LDL cholesterol, particularly where the two are discordant. LDL cholesterol can underestimate risk when particles are small and cholesterol-depleted, as in high triglycerides, metabolic syndrome, and type 2 diabetes; in these settings apolipoprotein B reveals a higher particle number and a truer risk. Practitioners order it to refine cardiovascular risk assessment beyond the standard lipid panel, to clarify risk in discordant or metabolically complex patients, and to guide and monitor the intensity of lipid-lowering therapy. It is interpreted against risk-stratified targets rather than a single reference value.
What does the Apo-B test measure?
Apolipoprotein B is the principal structural protein of the atherogenic lipoproteins — LDL, VLDL, IDL, and lipoprotein(a) — with one apolipoprotein B-100 molecule per particle. Because each atherogenic particle carries exactly one apolipoprotein B, the serum concentration provides a direct count of the total number of atherogenic particles, irrespective of how much cholesterol each carries. It is synthesised in the liver (apoB-100) and intestine (apoB-48), and the B-100 form is the focus of cardiovascular risk assessment.
Apolipoprotein B reflects the total burden of atherogenic particles and is a strong marker of cardiovascular risk, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content. It is particularly informative where LDL cholesterol underestimates risk — in high triglycerides, metabolic syndrome, diabetes, and discordance between particle number and cholesterol. It is increasingly used to refine risk and to guide and monitor lipid-lowering therapy.
Why is the Apo-B test ordered?
- Refinement of cardiovascular risk assessment beyond the standard lipid panel, particularly in intermediate-risk patients
- Assessment of patients with high triglycerides, metabolic syndrome, or type 2 diabetes, where LDL cholesterol underestimates atherogenic particle number
- Evaluation of discordance between LDL cholesterol and true particle burden, where apolipoprotein B clarifies risk
- Guiding the intensity of lipid-lowering therapy and monitoring response to treatment using particle number
- Assessment of residual risk in patients on statin therapy with apparently controlled LDL cholesterol
- Investigation of premature or familial cardiovascular disease as part of an advanced lipid assessment
- Evaluation of patients with a family history of cardiovascular disease where standard lipids underestimate risk
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — apolipoprotein B is reliable in the non-fasting state, consistent with modern lipid guidance
Collection method
Venipuncture at patient service centre
Turnaround
1–3 business days
Collection notes
Fasting is not required, as apolipoprotein B is stable in the non-fasting state. Document lipid-lowering therapy, as it lowers the result, and note pregnancy or acute illness, which affect interpretation. Best assessed when the patient is metabolically stable.
Specimen requirements
Minimum 0.5 mL serum. Separate serum from cells within 2 hours of collection.
What can affect Apo-B results?
Statins, ezetimibe, and PCSK9 inhibitors lower apolipoprotein B by reducing atherogenic particle number, so values reflect treatment as well as underlying risk and are used to monitor therapy.
Acute illness can transiently alter lipoprotein metabolism and apolipoprotein B, so assessment for baseline risk is best deferred until the patient is metabolically stable.
Physiological changes in lipoprotein metabolism during pregnancy raise apolipoprotein B, so values are not representative of baseline risk.
Poor glycaemic control and insulin resistance increase atherogenic particle production, raising apolipoprotein B; this reflects genuine risk but should be interpreted with the metabolic context.
Recent heavy alcohol intake and dietary extremes can shift lipoprotein metabolism, modestly affecting apolipoprotein B around the time of collection.
Renal protein loss and hepatic dysfunction alter lipoprotein synthesis and clearance, changing apolipoprotein B independent of primary cardiovascular risk.
What do Apo-B results mean?
Elevated
An elevated apolipoprotein B indicates a high number of atherogenic particles and greater cardiovascular risk, and may warrant or intensify lipid-lowering therapy. It is especially informative when high despite an apparently acceptable LDL cholesterol, revealing risk that the lipid panel understates, as in metabolic syndrome or diabetes.
Normal
A value within the desirable range suggests lower atherogenic particle burden, interpreted against the patient's overall risk and treatment targets rather than a single threshold. Risk-stratified goals mean the same value can be acceptable in a low-risk patient and inadequate in a high-risk one.
Reduced
A low apolipoprotein B reflects a low atherogenic particle burden and lower cardiovascular risk, and is the goal of lipid-lowering therapy in higher-risk patients. Low values on treatment indicate effective particle reduction.
Note: Apolipoprotein B is interpreted against risk-stratified targets, not a single normal range, and its main value is in revealing risk where LDL cholesterol and particle number diverge. It captures particle number but not particle size or composition, and does not replace assessment of the full lipid profile and global risk. Lipoprotein(a) carries apolipoprotein B and contributes to the value, which is relevant in patients with high Lp(a).
Frequently asked questions
It counts the total number of atherogenic lipoprotein particles, because each LDL, VLDL, IDL, and lipoprotein(a) particle carries exactly one apolipoprotein B. This gives a direct measure of particle burden rather than cholesterol content.
How to access the Apo-B test
The Apo-B reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: June 3, 2026
Last reviewed: June 3, 2026
- Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. (2019)
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. (2020)
- Wilkins JT, et al. Discordance between Apolipoprotein B and LDL-Cholesterol. J Am Coll Cardiol. (2016)
- Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. (2019)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…
cardiovascular
Lp(a)
The lipoprotein(a) [Lp(a)] test measures a genetically determined, LDL-like particle that is an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Because its level is largely inherited and stable through life, a single measurement usually suffices to establish lifelong risk.
cardiovascular
LDL Cholesterol
The LDL Cholesterol test measures the concentration of cholesterol carried within low-density lipoprotein particles in serum, serving as the cornerstone lipid parameter for cardiovascular risk assessment, lipid-lowering therapy initiation, and treatment-to-target monitoring.